FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2355403378> ?p ?o ?g. }

• W2355403378 endingPage "46" @default.
• W2355403378 startingPage "36" @default.
• W2355403378 abstract "BackgroundDaclizumab has been evaluated in multicentre, randomised, double-blind studies for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Safety and tolerability are key considerations in MS treatment selection, as they influence adherence to medication.ObjectiveEvaluate the safety of daclizumab in patients with RRMS from an integrated analysis of six clinical studies.MethodsPatients treated with at least one dose of subcutaneous daclizumab 150 mg or 300 mg monthly in three completed and three ongoing clinical studies were included in this integrated analysis. Cumulative incidence of treatment-emergent adverse events (AEs) was the primary endpoint.ResultsThis analysis included 2236 patients with 5214 patient-years of exposure to daclizumab. The cumulative incidence of any AE was 84% and of any serious AE excluding MS relapse was 16%. The incidences of AEs when evaluated by 6-month intervals remained stable over the 6.5 years of maximum follow-up. Most AEs were mild or moderate in severity. An important safety concern associated with daclizumab therapy involved hepatic AEs (16%) and serum transaminase elevations at least three times the upper limit of normal (10%), most of which were asymptomatic, self-limiting, and non-recurring. Cumulative incidences of cutaneous, infectious, and gastrointestinal AEs were 33%, 59%, and 25%, respectively; most events either resolved spontaneously or were treated successfully with standard medical interventions and did not result in discontinuation of treatment.ConclusionThis integrated analysis demonstrates that treatment of RRMS with daclizumab for periods of up to 6.5 years is associated with an acceptable safety profile with no evidence of cumulative toxicity over time." @default.
• W2355403378 created "2016-06-24" @default.
• W2355403378 creator A5004417493 @default.
• W2355403378 creator A5004837566 @default.
• W2355403378 creator A5006041455 @default.
• W2355403378 creator A5011944665 @default.
• W2355403378 creator A5015754502 @default.
• W2355403378 creator A5018185771 @default.
• W2355403378 creator A5020016996 @default.
• W2355403378 creator A5054874316 @default.
• W2355403378 creator A5062220148 @default.
• W2355403378 creator A5080279805 @default.
• W2355403378 date "2016-09-01" @default.
• W2355403378 modified "2023-10-15" @default.
• W2355403378 title "Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies" @default.
• W2355403378 cites W1568663209 @default.
• W2355403378 cites W2041816447 @default.
• W2355403378 cites W2097145477 @default.
• W2355403378 cites W2103445898 @default.
• W2355403378 cites W2112079575 @default.
• W2355403378 cites W2113485611 @default.
• W2355403378 cites W2113754168 @default.
• W2355403378 cites W2153142861 @default.
• W2355403378 cites W2159596132 @default.
• W2355403378 cites W2167414238 @default.
• W2355403378 cites W2171375112 @default.
• W2355403378 cites W2330965779 @default.
• W2355403378 cites W4211254511 @default.
• W2355403378 doi "https://doi.org/10.1016/j.msard.2016.05.010" @default.
• W2355403378 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27645341" @default.
• W2355403378 hasPublicationYear "2016" @default.
• W2355403378 type Work @default.
• W2355403378 sameAs 2355403378 @default.
• W2355403378 citedByCount "41" @default.
• W2355403378 countsByYear W23554033782016 @default.
• W2355403378 countsByYear W23554033782017 @default.
• W2355403378 countsByYear W23554033782018 @default.
• W2355403378 countsByYear W23554033782019 @default.
• W2355403378 countsByYear W23554033782020 @default.
• W2355403378 countsByYear W23554033782021 @default.
• W2355403378 countsByYear W23554033782022 @default.
• W2355403378 countsByYear W23554033782023 @default.
• W2355403378 crossrefType "journal-article" @default.
• W2355403378 hasAuthorship W2355403378A5004417493 @default.
• W2355403378 hasAuthorship W2355403378A5004837566 @default.
• W2355403378 hasAuthorship W2355403378A5006041455 @default.
• W2355403378 hasAuthorship W2355403378A5011944665 @default.
• W2355403378 hasAuthorship W2355403378A5015754502 @default.
• W2355403378 hasAuthorship W2355403378A5018185771 @default.
• W2355403378 hasAuthorship W2355403378A5020016996 @default.
• W2355403378 hasAuthorship W2355403378A5054874316 @default.
• W2355403378 hasAuthorship W2355403378A5062220148 @default.
• W2355403378 hasAuthorship W2355403378A5080279805 @default.
• W2355403378 hasBestOaLocation W23554033781 @default.
• W2355403378 hasConcept C120665830 @default.
• W2355403378 hasConcept C121332964 @default.
• W2355403378 hasConcept C126322002 @default.
• W2355403378 hasConcept C197934379 @default.
• W2355403378 hasConcept C203014093 @default.
• W2355403378 hasConcept C203092338 @default.
• W2355403378 hasConcept C2778375690 @default.
• W2355403378 hasConcept C2778715236 @default.
• W2355403378 hasConcept C2779719350 @default.
• W2355403378 hasConcept C2780640218 @default.
• W2355403378 hasConcept C2909675724 @default.
• W2355403378 hasConcept C2911091166 @default.
• W2355403378 hasConcept C535046627 @default.
• W2355403378 hasConcept C61511704 @default.
• W2355403378 hasConcept C71924100 @default.
• W2355403378 hasConcept C72563966 @default.
• W2355403378 hasConcept C88879693 @default.
• W2355403378 hasConceptScore W2355403378C120665830 @default.
• W2355403378 hasConceptScore W2355403378C121332964 @default.
• W2355403378 hasConceptScore W2355403378C126322002 @default.
• W2355403378 hasConceptScore W2355403378C197934379 @default.
• W2355403378 hasConceptScore W2355403378C203014093 @default.
• W2355403378 hasConceptScore W2355403378C203092338 @default.
• W2355403378 hasConceptScore W2355403378C2778375690 @default.
• W2355403378 hasConceptScore W2355403378C2778715236 @default.
• W2355403378 hasConceptScore W2355403378C2779719350 @default.
• W2355403378 hasConceptScore W2355403378C2780640218 @default.
• W2355403378 hasConceptScore W2355403378C2909675724 @default.
• W2355403378 hasConceptScore W2355403378C2911091166 @default.
• W2355403378 hasConceptScore W2355403378C535046627 @default.
• W2355403378 hasConceptScore W2355403378C61511704 @default.
• W2355403378 hasConceptScore W2355403378C71924100 @default.
• W2355403378 hasConceptScore W2355403378C72563966 @default.
• W2355403378 hasConceptScore W2355403378C88879693 @default.
• W2355403378 hasFunder F4320333023 @default.
• W2355403378 hasLocation W23554033781 @default.
• W2355403378 hasLocation W23554033782 @default.
• W2355403378 hasOpenAccess W2355403378 @default.
• W2355403378 hasPrimaryLocation W23554033781 @default.
• W2355403378 hasRelatedWork W1966250111 @default.
• W2355403378 hasRelatedWork W1999001339 @default.
• W2355403378 hasRelatedWork W2008490960 @default.
• W2355403378 hasRelatedWork W2050173858 @default.
• W2355403378 hasRelatedWork W2074936215 @default.

• next